Cargando…
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution o...
Autores principales: | Li, Dateng, Xu, Meng, Hooper, Andrea T., Rofail, Diana, Mohammadi, Kusha A., Chen, Yiziying, Ali, Shazia, Norton, Thomas, Weinreich, David M., Musser, Bret J., Hamilton, Jennifer D., Geba, Gregory P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/ https://www.ncbi.nlm.nih.gov/pubmed/37550377 http://dx.doi.org/10.1038/s41598-023-39681-7 |
Ejemplares similares
-
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022) -
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
por: Isa, Flonza, et al.
Publicado: (2022) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022) -
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
por: Hooper, Andrea T., et al.
Publicado: (2022)